Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial
Sircar G et al. Rheumatology (Oxford) 2018: key213. doi: 10.1093/rheumatology/key213
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.